Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors

It is a current regulatory requirement to demonstrate absence of detectable replication-competent lentivirus (RCL) in lentiviral vector products prior to use in clinical trials. Immune Design previously described an HIV-1-based integration-deficient lentiviral vector for use in cancer immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Farley, Daniel C, McCloskey, Laura, Thorne, Barbara A, Tareen, Semih U, Nicolai, Christopher J, Campbell, David J, Bannister, Richard, Stewart, Hannah J, Pearson, Laura JE, Moyer, Bentley J, Robbins, Scott H, Zielinski, Leah, Kim, Tae, Radcliffe, Pippa A, Mitrophanous, Kyriacos A, Gombotz, Wayne R, Miskin, James E, Kelley-Clarke, Brenna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445008/
https://www.ncbi.nlm.nih.gov/pubmed/26029728
http://dx.doi.org/10.1038/mtm.2015.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445008/
https://www.ncbi.nlm.nih.gov/pubmed/26029728
http://dx.doi.org/10.1038/mtm.2015.17

Ejemplares similares